HealthcareServices

Global Giant-Cell Arteritis Market 2026–2030: Forecast Insights for Business Planning

February 27, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the giant-cell arteritis market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Giant-Cell Arteritis Market be in 2030 compared with 2026?

The giant-cell arteritis market has shown steady expansion over recent years. It is anticipated to increase from $1.12 billion in 2025 to $1.18 billion in 2026, achieving a compound annual growth rate (CAGR) of 4.9%. This past growth can be ascribed to factors such as the rise in the aging population, the continued use of corticosteroid therapy, better rheumatology care, the expansion of hospital-based treatment options, and heightened awareness of the disease.

The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.3%. Factors contributing to this growth during the projection period include the approval of new biologic drugs, advancements in immunology research, enhanced diagnostic procedures, tailored vasculitis treatments, and an increase in specialized clinics. Key trends identified for the forecast timeframe encompass a greater uptake of biologic therapies, a heightened emphasis on prompt and precise diagnosis, broader application of corticosteroid-sparing treatments, enhanced long-term disease surveillance, and increasing recognition of methods to prevent vision loss.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

What Drivers Are Guiding Growth Patterns In The Giant-Cell Arteritis Market?

The giant-cell arteritis market is expected to grow due to a rising focus on personalized medicine. This approach customizes medical treatments according to individual characteristics, such as genetics, lifestyle, and environment. The expansion of personalized medicine is driven by advances in genomics, biotechnology, and data analytics, which enable targeted therapies that boost treatment effectiveness and minimize adverse effects for patients. In the context of giant-cell arteritis (GCA), personalized medicine can facilitate specific therapies based on individual patient factors like genetic predispositions, immune profiles, and disease manifestations. For example, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, stated that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. During 2023, the FDA approved 16 new personalized treatments specifically for rare diseases, marking a significant increase from six approvals in 2022. Furthermore, the 2023 approvals also covered seven cancer medications and three treatments for various other diseases and conditions. Therefore, the growing emphasis on personalized medicine is a key factor driving the growth of the giant-cell arteritis market.

Which Segments Are Driving Activity In The Giant-Cell Arteritis Market?

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

Which Trends Are Influencing The Performance And Direction Of The Giant-Cell Arteritis Market?

Leading companies involved in giant-cell arteritis are creating novel products, including biosimilars, to broaden available treatments and cater to patients’ outstanding medical requirements. A biosimilar is a biological medicine that closely resembles an existing approved biological product, demonstrating no significant clinical variations in its safety, purity, or potency. For example, Fresenius SE & Co. KGaA, a healthcare firm based in Germany, introduced Tocilizumab-aazg in the US in April 2024 for the management of chronic autoimmune conditions. This particular biosimilar has received approval for treating conditions like rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. The approval was granted following data from a randomized, double-blind, single-dose, parallel phase 1 trial that assessed its pharmacokinetics, safety, and immunogenicity against both US and EU reference tocilizumab across three distinct patient cohorts.

Which Key Players Are Driving Competition In The Giant-Cell Arteritis Market?

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

Which Region Currently Holds The Largest Share Of The Giant-Cell Arteritis Market?

North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Giant-Cell Arteritis Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2026, By The Business Research Company

Rare Inflammatory Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-inflammatory-disease-treatment-global-market-report

Small Cell Backhaul Market Report 2026

https://www.thebusinessresearchcompany.com/report/small-cell-backhaul-global-market-report

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795